Nektar Therapeutics (NKTR) EBT (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly EBT of -$43.1 million for Q1 2026, up 7.07% year-over-year from -$40.2 million in Q1 2025, and down 24.17% quarter-over-quarter from -$34.7 million in Q4 2025.
Nektar Therapeutics (NKTR) EBT (2010 - 2026) Analysis & Trends
Nektar Therapeutics' EBT history runs 17 years deep, the most recent figure standing at -$43.1 million for Q1 2026.
- In Q1 2026, EBT rose 7.07% year-over-year to -$43.1 million; the TTM figure through Mar 2026 stood at -$152.2 million (down 18.24% YoY), while the FY2025 annual figure was -$155.5 million, down 30.44% from the prior year.
- EBT for Q1 2026 stood at -$43.1 million, down from -$34.7 million in the prior quarter.
- The five-year high for EBT was $7.0 million in Q4 2024, with the low at -$159.0 million in Q2 2022.
- The 5-year median for EBT is -$45.9 million (2023), against an average of -$56.4 million.
- The sharpest annual moves came in 2024 and 2025: EBT soared 116.63% in 2024, then tumbled 595.6% in 2025.
- Nektar Therapeutics' EBT stood at -$56.5 million in 2022, then grew by 25.53% to -$42.1 million in 2023, then surged by 116.63% to $7.0 million in 2024, then sank by 595.6% to -$34.7 million in 2025, then declined by 24.17% to -$43.1 million in 2026.
- Business Quant data shows NKTR's EBT at -$43.1 million in Q1 2026, -$34.7 million in Q4 2025, and -$35.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -43.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.09 Mn |
| Dec 31, 2025 | -34.70 Mn |
| Sep 30, 2025 | -35.02 Mn |
| Jun 30, 2025 | -39.40 Mn |
| Mar 31, 2025 | -46.37 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Sep 30, 2024 | -37.05 Mn |
| Jun 30, 2024 | -52.32 Mn |
| Mar 31, 2024 | -36.84 Mn |
| Dec 31, 2023 | -42.11 Mn |
| Sep 30, 2023 | -45.90 Mn |
| Jun 30, 2023 | -51.17 Mn |
| Mar 31, 2023 | -137.08 Mn |
| Dec 31, 2022 | -56.54 Mn |
| Sep 30, 2022 | -59.20 Mn |
| Jun 30, 2022 | -158.97 Mn |
| Mar 31, 2022 | -90.27 Mn |
| Dec 31, 2021 | 378.79 Mn |
| Sep 30, 2021 | -129.59 Mn |
| Jun 30, 2021 | -125.16 Mn |